Drug Insight: the role of statins in combination with ezetimibe to lower LDL cholesterol
Antonio M Gotto Jr* and John A Farmer
Correspondence *c/o Mr Jesse Jou, Weill Medical College of Cornell University, 445 East 69th Street, OH205, New York, NY 10021, USA
Email amg_editorial@med.cornell.edu
The cardiovascular benefits of statin therapy are well documented; however, no trial has identified a target level for LDL cholesterol below which no further benefit of treatment is seen. With the introduction of more-aggressive optional LDL-cholesterol targets in US guidelines, Antonio Gotto and John Farmer consider the rationale for combination therapy of statins with the cholesterol absorption inhibitor ezetimibe.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A new feature on the cholesterol-lowering landscapeNature Medicine News and Views (01 Dec 2001)
Immunomodulation: a new role for statins?Nature Medicine News and Views (01 Dec 2000)
RESEARCH
Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover StudyClinical Pharmacology & Therapeutics Article Response
See all 9 matches for Research